Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6712477 | 0.91 | KCNH2 (0.44) | F10NPC1RAB9AF2KCNH2 | |
| SCHEMBL6716150 | 0.90 | F10 (0.42) | F10KCNH2 | |
| SCHEMBL6711450 | 0.87 | F10 (0.45) | F10KCNH2MEN1KMT2A | |
| SCHEMBL7013030 | 0.86 | F10 (0.31) | F10WDR5 | |
| SCHEMBL6711451 | 0.86 | F10 (0.40) | F10 | |
| SCHEMBL6712514 | 0.86 | F10 (0.41) | F10NPC1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL6714441 | 0.84 | MEN1 (0.38) | F10TP53SMN1; SMN2MEN1MAPT | |
| SCHEMBL6712468 | 0.82 | F10 (0.40) | F10KCNH2 | |
| SCHEMBL6718580 | 0.78 | F10 (0.46) | F10F2KCNH2ALDH1A1 | |
| SCHEMBL5536664 | 0.73 | F10 (0.40) | F10NPC1TP53CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077690-A1 | Quaternary amidino based inhibitors of factor xa | F12, TFPI, F11 | F10 15/4885NPC1 2651/4885TP53 3489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.